ArticleFrontiers in veterinary science2025
Gastrointestinal flora and serum metabolomic elucidation of
Article in Frontiers in veterinary science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This study addresses the global challenge of subclinical bovine mastitis (SCBM) in dairy cows, a prevalent disease causing substantial economic losses, by investigating the mechanistic basis of Methods: Initially, the active components of Results: ARWD administration dose-dependently improved milk yield and protein content while reducing somatic cell counts. Serum pro-inflammatory cytokines (TNF-α, IL-6, IL-1β) decreased, contrasting with increases in immunoglobulins (IgA, IgM, IgG) and enhanced superoxide dismutase activity. Microbiota restructuring featured ruminal enrichment of Bifidobacterium and fecal dominance of Rikenellaceae_RC9_gut_group, coupled with suppression of pro-inflammatory taxa (e.g., Christensenellaceae_R-7_group). Metabolomic analysis identified four ARWD-responsive biomarkers, notably Spirotaccagenin and Pelanin, operating through linoleic acid metabolism and phospholipase D signaling pathways. Strong correlations linked microbial shifts to improved lactation parameters and reduced inflammation. Conclusion: The findings establish that ARWD alleviates SCBM through coordinated microbiota remodeling and metabolic reprogramming, specifically enhancing antioxidant defenses, restoring mammary barrier integrity, and modulating immune-inflammation crosstalk, with optimal efficacy at 0.4 g·kg
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.